Roivant Sciences Ltd (ROIV)
Pretax margin
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -681,590 | 4,253,430 | -1,224,830 | -923,747 | -898,547 |
| Revenue | US$ in thousands | 29,053 | 124,795 | 61,280 | 55,286 | 23,795 |
| Pretax margin | -2,346.02% | 3,408.33% | -1,998.74% | -1,670.85% | -3,776.20% |
March 31, 2025 calculation
Pretax margin = EBT ÷ Revenue
= $-681,590K ÷ $29,053K
= -2,346.02%
The pretax margin of Roivant Sciences Ltd has shown significant variability over the years.
In March 2021, the company reported a very low pretax margin of -3,776.20%, indicating that its pre-tax income was heavily negative relative to its revenue.
By March 2022, there was a slight improvement as the pretax margin improved to -1,670.85%, although it remained in negative territory.
The trend continued in March 2023, with a pretax margin of -1,998.74%, suggesting ongoing operational challenges impacting profitability.
In March 2024, there was a notable turnaround as the company achieved a pretax margin of 3,408.33%, signifying a substantial improvement in profitability and efficiency in generating pre-tax income.
The absence of data for March 2025 makes it difficult to assess the most recent performance. Overall, Roivant Sciences Ltd has experienced significant fluctuations in its pretax margin, highlighting the importance of closely monitoring and managing profitability levels.
Peer comparison
Mar 31, 2025